BACKGROUND: Long-term bisphosphonate use has often been associated with atypical femoral fractures. These fractures evolve from incomplete femoral fractures. A previous study demonstrated that the presence of a radiolucent line in an incomplete fracture can indicate a high risk of progression to complete fracture. QUESTIONS/PURPOSES: The aim of this study is to present a management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. Specific study questions include the following: (1) Is there a difference in the prognosis of these fractures based on the presence or absence of a radiolucent fracture line? (2) Can treatment with teriparatide assist in clinical/radiographic healing of these incomplete fractures? (3) Is there a characteristic biochemical profile in these patients? PATIENTS AND METHODS: We retrospectively examined all femur radiographs ordered by the metabolic bone disease service at our hospital between July 1, 2006 and July 1, 2011 and identified 10 patients with a total of 14 incomplete fractures. Nine patients received bisphosphonates for a mean duration of 10 ± 5 years (range, 4-17). The mean follow-up since the time of diagnosis was 20 ± 11 months (range, 6-36 months). RESULTS: Five fractures did not have a radiolucent fracture line and were treated conservatively with partial weight-bearing restrictions and pharmacologic therapy. All five of these fractures healed with conservative management. Nine fractures had a radiolucent fracture line, and only two of these were treated successfully with conservative management including teriparatide. Six of the eight patients with a radiolucent line elected for surgical prophylaxis after 3 months of conservative management, whereas one patient underwent surgical prophylaxis without a trial of conservative management. Regarding the biochemical profiles, bone turnover markers for our patient cohort were in the lower quartile. CONCLUSIONS: Fractures without a radiolucent line appear to respond to conservative management and not require surgical prophylaxis. Teriparatide treatment may hold promise in promoting healing of these fractures.
BACKGROUND: Long-term bisphosphonate use has often been associated with atypical femoral fractures. These fractures evolve from incomplete femoral fractures. A previous study demonstrated that the presence of a radiolucent line in an incomplete fracture can indicate a high risk of progression to complete fracture. QUESTIONS/PURPOSES: The aim of this study is to present a management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. Specific study questions include the following: (1) Is there a difference in the prognosis of these fractures based on the presence or absence of a radiolucent fracture line? (2) Can treatment with teriparatide assist in clinical/radiographic healing of these incomplete fractures? (3) Is there a characteristic biochemical profile in these patients? PATIENTS AND METHODS: We retrospectively examined all femur radiographs ordered by the metabolic bone disease service at our hospital between July 1, 2006 and July 1, 2011 and identified 10 patients with a total of 14 incomplete fractures. Nine patients received bisphosphonates for a mean duration of 10 ± 5 years (range, 4-17). The mean follow-up since the time of diagnosis was 20 ± 11 months (range, 6-36 months). RESULTS: Five fractures did not have a radiolucent fracture line and were treated conservatively with partial weight-bearing restrictions and pharmacologic therapy. All five of these fractures healed with conservative management. Nine fractures had a radiolucent fracture line, and only two of these were treated successfully with conservative management including teriparatide. Six of the eight patients with a radiolucent line elected for surgical prophylaxis after 3 months of conservative management, whereas one patient underwent surgical prophylaxis without a trial of conservative management. Regarding the biochemical profiles, bone turnover markers for our patient cohort were in the lower quartile. CONCLUSIONS:Fractures without a radiolucent line appear to respond to conservative management and not require surgical prophylaxis. Teriparatide treatment may hold promise in promoting healing of these fractures.
Authors: C H Chesnut; S Silverman; K Andriano; H Genant; A Gimona; S Harris; D Kiel; M LeBoff; M Maricic; P Miller; C Moniz; M Peacock; P Richardson; N Watts; D Baylink Journal: Am J Med Date: 2000-09 Impact factor: 4.965
Authors: Stephen J Gomberg; Rosanna L Wustrack; Nicola Napoli; Claude D Arnaud; Dennis M Black Journal: J Clin Endocrinol Metab Date: 2011-03-23 Impact factor: 5.958
Authors: M C Ellerington; T C Hillard; S I Whitcroft; M S Marsh; B Lees; L M Banks; M I Whitehead; J C Stevenson Journal: Calcif Tissue Int Date: 1996-07 Impact factor: 4.333
Authors: U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus Journal: N Engl J Med Date: 1995-11-30 Impact factor: 91.245
Authors: Andrew Petraszko; Daniel Siegal; Michael Flynn; Sudhaker D Rao; Ed Peterson; Marnix van Holsbeeck Journal: Skeletal Radiol Date: 2016-02-10 Impact factor: 2.199
Authors: Katrina Harborne; Jonathan M Hazlehurst; Hari Shanmugaratnam; Samuel Pearson; Alison Doyle; Neil J Gittoes; Surabhi Choudhary; Rachel K Crowley Journal: Br J Radiol Date: 2015-10-28 Impact factor: 3.039
Authors: H Tsuchie; N Miyakoshi; K Iba; Y Kasukawa; K Nozaka; T Dohke; I Kosukegawa; T Aizawa; S Maekawa; H Abe; M Takeshima; T Tomite; T Segawa; K Ouchi; H Kinoshita; M Suzuki; T Yamashita; Y Shimada Journal: Osteoporos Int Date: 2018-08-13 Impact factor: 4.507